Preclinical models of endometriosis and interstitial cystitis/bladder pain syndrome: an Innovative Medicines Initiative-PainCare initiative to improve their value for translational research in pelvic pain
Authors:
- Paulina Nunez-BadinezPaulina Nunez-Badinez
- Bianca De LeoBLBianca De Leo
- Alexis Laux-BiehlmannALAlexis Laux-Biehlmann
- Anja HoffmannAHAnja Hoffmann
- Thomas M. ZollnerTZThomas M. Zollner
- Philippa T.K. SaundersPhilippa T.K. Saunders
- Ioannis SimitsidellisISIoannis Simitsidellis
- Ana CharruaACAna Charrua
- Francisco CruzFCFrancisco Cruz
- Miguel Angel TejadaMTMiguel Angel Tejada
- Stephen B. McMahonSMStephen B. McMahon
Open Access
- 3 March 2021
- journal article
- review article
- Published by Wolters Kluwer Health in Pain
- Vol. 162 (9) , 2349-2365
Abstract
Endometriosis (ENDO) and interstitial cystitis/bladder pain syndrome (IC/BPS) are chronic pain conditions for which better treatments are urgently needed. Development of new therapies with proven clinical benefit has been slow. We have conducted a review of existing preclinical in vivo models for ENDO and IC/BPS in rodents, discussed to what extent they replicate the phenotype and pain experience of patients, as well as their relevance for translational research. In 1009 publications detailing ENDO models, 41% used autologous, 26% syngeneic, 18% xenograft, and 11% allogeneic tissue in transplantation models. Intraperitoneal injection of endometrial tissue was the subcategory with the highest construct validity score for translational research. From 1055 IC/BPS publications, most interventions were bladder-centric (85%), followed by complex mechanisms (8%) and stress-induced models (7%). Within these categories, the most frequently used models were instillation of irritants (92%), autoimmune (43%), and water avoidance stress (39%), respectively. Notably, although pelvic pain is a hallmark of both conditions and a key endpoint for development of novel therapies, only a small proportion of the studies (models of ENDO: 0.5-12%, models of IC/BPS: 20-44%) examined endpoints associated with pain. Moreover, only 2% and 3% of publications using models of ENDO and IC/BPS investigated non-evoked pain endpoints. This analysis highlights the wide variety of models used, limiting reproducibility and translation of results. We recommend refining models so that they better reflect clinical reality, sharing protocols, and employing standardized endpoints to improve reproducibility. We are addressing this in our project IMI-PainCare/Translational Research in Pelvic Pain (TRiPP).Keywords
This publication has 130 references indexed in Scilit:
- MCP-1-Induced Histamine Release from Mast Cells Is Associated with Development of Interstitial Cystitis/Bladder Pain Syndrome in Rat ModelsMediators of Inflammation, 2012
- A mouse model for interstitial cystitis/painful bladder syndrome based on APF inhibition of bladder epithelial repair: a pilot studyBMC Urology, 2012
- Retinoic acid suppresses growth of lesions, inhibits peritoneal cytokine secretion, and promotes macrophage differentiation in an immunocompetent mouse model of endometriosisFertility and Sterility, 2012
- BALB/c-Fcgr2b−/−Pdcd1−/− mouse expressing anti-urothelial antibody is a novel model of autoimmune cystitisScientific Reports, 2012
- Autoimmunity to Uroplakin II Causes Cystitis in Mice: A Novel Model of Interstitial CystitisEuropean Urology, 2012
- Endometriosis and infertilityJournal of Assisted Reproduction and Genetics, 2010
- EndometriosisNew England Journal of Medicine, 2010
- Pharmacologic attenuation of pelvic pain in a murine model of interstitial cystitisBMC Urology, 2009
- Footshock-Induced Urinary Bladder Hypersensitivity: Role of Spinal Corticotropin-Releasing Factor ReceptorsThe Journal of Pain, 2008
- RDP58 inhibits T cell-mediated bladder inflammation in an autoimmune cystitis modelJournal of Autoimmunity, 2008